Annals of Thoracic Medicine Official publication of the Saudi Thoracic Society, affiliated to King Saud University
Search Ahead of print Current Issue Archives Instructions Subscribe e-Alerts Login 
Home Email this article link Print this article Bookmark this page Decrease font size Default font size Increase font size

    Article Cited by others


Safety and efficacy of gefapixant, a novel drug for the treatment of chronic cough: A systematic review and meta-analysis of randomized controlled trials

Abu-Zaid Ahmed, Aljaili Aseel Khalid, Althaqib Amnah, Adem Fatima, Alhalal Doaa Ali, Almubarak Amena Faiq, Aldughaither Saud Musaab, Alghabban Sarah Ali, Alfaraj Ghaidaa, Masoud Ahmed Taher, Alsuhaibani Nujud Abdullah

Year : 2021| Volume: 16| Issue : 2 | Page no: 127-140

   This article has been cited by
1 P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough
Wen-Wen Cui, Si-Yu Wang, Yu-Qing Zhang, Yao Wang, Ying-Zhe Fan, Chang-Run Guo, Xing-Hua Li, Yun-Tao Lei, Wen-Hui Wang, Xiao-Na Yang, Motoyuki Hattori, Chang-Zhu Li, Jin Wang, Ye Yu
Computational and Structural Biotechnology Journal. 2022;
[Pubmed]  [Google Scholar] [DOI]
2 Risk Factors for Persistent Chronic Cough During Consecutive Years: A Retrospective Database Analysis
Robert S. Zeiger, Michael Schatz, Yichen Zhou, Fagen Xie, Vishal Bali, Jonathan Schelfhout, Amar Das, Julie A. Stern, Wansu Chen
The Journal of Allergy and Clinical Immunology: In Practice. 2022;
[Pubmed]  [Google Scholar] [DOI]
3 Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19
Malek Zarei, Navideh Sahebi Vaighan, Seyed Ali Ziai
Immunopharmacology and Immunotoxicology. 2021; 43(6): 633
[Pubmed]  [Google Scholar] [DOI]


Read this article